Tag:
generic competition
Latest Headlines
Latest Headlines
Lilly shares slide on second big patent setback
Eli Lilly ( NYSE: LLY ) has been hit with yet another key loss on the generic drug front, losing its case in federal court to protect its patent for the ADHD drug Strattera. And this one could prove
Senate tacks 'pay-for-delay' ban onto spending bill
Last week, the drug business got a reprieve on a proposed "pay-for-delay" ban when the Senate tossed the measure from a war-funding bill. But that reprieve was only temporary. Yesterday, the Senate
Nod for Lovenox copy cuts into Sanofi forecast
Sound the alarm on Lovenox--generic competition is coming. The Sanofi-Aventis ( NYSE: SNY ) blood thinner will see its first copycat rival now that Sandoz, the generics arm of Novartis, has won FDA
AstraZeneca wins key Crestor patent fight
AstraZeneca ( NYSE: AZN ) won a pivotal court victory when a judge in Delaware overruled a patent challenge to Crestor, its blockbuster cholesterol drug. Judge Joseph Farnan upheld AstraZeneca's
Pfizer vows to fight Lipitor copies in Canada
Generic forms of Pfizer's ( NYSE: PFE ) blockbuster Lipitor cholesterol fighter began flooding into Canada on Wednesday, in a taste of what is to come for the $12 billion-a-year drug next year in the
It's getting tougher to ride the generics-growth wave
Everyone knows that generic competition is a big problem for Big Pharma. But generics competition is also becoming a big problem for ... generics makers. Although their share of U.S. prescriptions
FDA denies Cephalon's bid for Nuvigil in jet lag
Cephalon got a one-two punch from the U.S. government yesterday. The FDA refused to approve its alertness drug Nuvigil to fight jet lag, a key element of the company's strategy for switching patients
Leibowitz urges pay-for-delay legislation
FTC Chairman Jon Leibowitz says the need for legislation prohibiting illegal pay-for-delay settlements remains--even though a ban on such deals has been dropped from the healthcare reform bill .
Pay-for-delay ban dropped from reform bill
Healthcare reform just started to look better for pharma: That ban on pay-for-delay deals has been dropped from the legislation. The provision would have barred patent settlements in which generics
Will generic Wellbutrin live up to brand?
It's not often that we get data on patients switching from a branded med to a rival generic. But complaints about Teva Pharmaceutical Industries' version of the antidepressant Wellbutrin XL drove FDA
